The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

Sallman D., Asch A., Kambhampati S., Al Malki M., Zeidner J., Donnellan W., Lee D., Vyas P., Jeyakumar D., Mannis G., Tanaka T., Chai-Ho W., Larson R., Whiteley A., Marcucci G., Komrokji R., Garcia-Manero G., Van Elk J., Lin M., Maute R., Volkmer J-P., Takimoto C., Chao M., Daver N.

Type

Conference paper

Publication Date

2021-01-01T00:00:00+00:00

Volume

21

Pages

S290 - S290

Keywords

AML, myeloid malignancies, leukemia stem cells, TP53, CD47

Permalink Close